Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AYTU The NASDAQ Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38247 AYTU BIOPHARMA, INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | --- | --- | |------------------------------------------------------- ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript September 27, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. I ...

Aytu BioPharma, Inc. Nasdaq: AYTU Forward Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will, ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Naz Rahman - Maxim Group, LLC Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please note this conference is ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AYTU The NASDAQ Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2023 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Vernon Bernardino - H.C. Wainwright Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q2 Results Conference Call. At this time, all participants are on a listen-only mode. [Operator Instructions]. Please note this co ...

Revenue and Profit - For the three months ended December 31, 2022, net product revenue increased by $3.2 million, or 14%, compared to the same period in 2021, driven primarily by growth in the Pediatric Portfolio [175]. - Gross profit for the three months ended December 31, 2022, was $17.3 million, an increase of $5.0 million, or 41%, compared to the same period in 2021, with gross margin percentage rising to 66% [179]. Expenses and Losses - Research and development expenses decreased by $2.8 million, or 62%, for the three months ended December 31, 2022, due to the suspension of development programs AR101 and Healight [181]. - Operating expenses totaled $24.1 million for the three months ended December 31, 2022, a slight increase of $0.5 million compared to the same period in 2021 [176]. - The company reported a net loss of $6.7 million for the three months ended December 31, 2022, compared to a net loss of $11.5 million in the same period in 2021, reflecting a reduction of $4.9 million [176]. - The company incurred an impairment charge of $2.6 million related to the cessation of active development of the NT0502 product candidate [184]. Future Projections and Savings - The company expects to save over $20 million in projected future study costs over the next three fiscal years due to the suspension of clinical development programs [165]. - The company entered into an agreement to extend the interest-only period of its senior secured loan facility, which is expected to conserve approximately $3.0 million in cash related to principal payments in 2023 [170]. Financial Position and Cash Flow - As of December 31, 2022, the accumulated deficit was $294.5 million, up from $287.1 million as of June 30, 2022 [164]. - Net cash used in operating activities totaled $11.6 million for the six months ended December 31, 2022, a decrease of $1.0 million compared to $12.6 million in the same period of 2021 [193]. - Net cash provided by financing activities was $11.7 million during the six months ended December 31, 2022, primarily from $9.1 million in proceeds from the August 2022 equity raise [196]. - As of December 31, 2022, approximately $82.4 million remains available under the 2021 Shelf registration statement [186]. Obligations and Liabilities - The company has obligations for fixed and contingent milestone payments totaling up to $16.0 million related to the acquisition of Innovus Pharmaceuticals, Inc. [202]. - The company may be required to pay up to $67.5 million in regulatory and commercial-based earn-out payments to Rumpus, contingent on milestone achievements [203]. - The company had $0.4 million accrued for plaintiff's attorney fees related to ongoing class-action securities litigations as of December 31, 2022 [211]. Strategic Initiatives - The company plans to evaluate strategic options for the Healight asset, including potential partnerships and modifications to existing licensing agreements [166]. - The company experienced significant inflationary pressure and supply chain disruptions during fiscal 2022 and 2023, which are expected to continue impacting operations [169]. Amortization and Gains - Amortization expense of intangible assets decreased by $0.3 million (20%) and $0.6 million (21%) for the three and six months ended December 31, 2022, respectively, compared to the same periods in 2021 [185]. - The company recognized an unrealized gain of $1.4 million and $3.6 million from derivative warrant liabilities for the three and six months ended December 31, 2022, respectively [185]. Loan Agreements - The Eclipse Loan Agreement provides up to $12.5 million in Revolving Loans, with a maturity date of January 26, 2025 [190].

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen, and welcome to the Aytu BioPharma Fiscal 2023 Q1 Results Call. At this time, all participants are placed on a listen-only mode and the floor for questions and comments after the presentation. It is now my pleasure to turn ...